Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07274228

Tamsulosin and the Risk of Serious Adverse Events

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

View on ClinicalTrials.gov

Summary

This is a population-based cohort study assessing whether initiating a higher dose of tamsulosin (0.8 mg/day) compared to a lower dose (0.4 mg/day) in older adults with advanced chronic kidney disease (CKD) (an estimated glomerular filtration rate (eGFR) \<45 mL/min per 1.73 m² but not receiving dialysis or having a history of kidney transplantation) is associated with a higher 90-day risk of a composite outcome of all-cause hospitalization or all-cause emergency visits or all-cause mortality.

Official title: Risk of Serious Adverse Events Associated With Tamsulosin Use in Older Adults With Advanced Chronic Kidney Disease: A Population-Based Cohort Study Research Protocol

Key Details

Gender

MALE

Age Range

66 Years - Any

Study Type

OBSERVATIONAL

Enrollment

14000

Start Date

2008-01-01

Completion Date

2027-12-31

Last Updated

2026-09-14

Healthy Volunteers

No

Interventions

DRUG

Tamsulosin

The primary exposure of interest will be oral tamsulosin at a dose of 0.4 mg/day, representing the median dose in high-throughput computing analyses. For the primary comparison, oral tamsulosin at a dose of 0.4 mg/day will be chosen to reduce the influence of indication bias.

Locations (1)

London Health Sciences Centre Research Institute

London, Ontario, Canada